You are here

Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Graz, , A-8036 Austria
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Osteoarthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Osteoarthritis of the knee or hip according to ACR criteria with Kellgren-Lawrence
X-ray grade equal to, or greater than, 2.

- Patients must be experiencing some benefit from their current stable dose regimen of
oral diclofenac 150 mg/day and be tolerating their diclofenac regimen.

- Pain and function levels as required by the protocol at Screening and Baseline.

- Willing to discontinue all non-study pain medications throughout the study except as
permitted per protocol.

- Willing and able to comply with lifestyle guidelines, scheduled visits, treatment
plan, laboratory tests and other study procedures.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Pregnant women.

- BMI greater than 39.

- History of other disease that may involve index knee or hip including inflammatory
joint diseases, chrystalline disease (gout or pseudogout), endocrinopathies, metabolic
joint diseases, lupus erythematosus, rheumatoid arthritis (RA), joint infections,
neuropathic disorders, avascular necrosis, Paget's disease or tumors.

- Fibromyalgia, regional pain caused by lumbar or cervical compression with
radiculopathy or other moderate to severe pain that may confound assessments or
self-evaluation of the pain associated with OA.

- Signs and symptoms of clinically significant cardiac disease within 6 months prior to
screening.

- Diagnosis or TIA within 6 months prior to screening or diagnosis of stroke with
residual deficits that would preclude completion of required study activities.

- History, diagnosis , signs or symptoms of clinically significant neurological and/or
psychiatric disease/disorder.

- At Screening: uncontrolled hypertension, hemoglobin A1c greater than or equal to 10%,
ALT or AST greater than or equal to 3X upper limit of normal, creatinine exceeding 150
micro-mol/L in men or 133 micro-mol/L in women.

- Patients on warfarin or other coumadin anticoagulant therapy and/or lithium therapy
within 30 days prior to Screening.

- Known hypersensitivity to NSAIDs (eg, diclofenac), cyclooxygenase inhibitors or
paracetamol (acetaminophen).

NCT00864097
Pfizer
Terminated
Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Chronic Pain, Hip Osteoarthritis, Knee Osteoarthritis
NCT02528188
All Genders
18+
Years
Multiple Sites
Hip Osteoarthritis, Knee Osteoarthritis
NCT02709486
All Genders
18+
Years
Multiple Sites
Osteoarthritis
NCT00392080
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now